Wednesday, June 9, 2010
Sunday, February 7, 2010
America developed a new tool for diagnosis and treatment of cancer
26, published a paper, said the researchers developed a gene mapping tool that can better diagnose and treatment of common tumors.
According to Agence France-Presse reported, this study focused on mapping the most common and deadly brain tumor molecular characteristics of early, resulting in nuclear magnetic resonance scanning to distinguish it belongs to what type of seeds.
The paper published in the United States, "National Academy of Sciences" magazine published an advance on. Paper the main author, University of California, San Diego, Michael? Guo (sound) said that the same method can also be used to better identify other tumor types.
Guo and his research team used samples to be tested in vivo for different sub-types of cancer genetic structure, mapping, and these results provide in vivo mapping of samples of patients with MRI scan results were compared.
He said: "This is a powerful, scalable technology. It can be with different combination of scanning technology, but also can be applied to different types of tumors, such as liver cancer."
Although this technology for clinical applications still need to undergo further tests before, but it can help doctors confirm the future, what kind of treatment for the tumor sub-types of what to design a better treatment programs.
Guo said: "The medical goal is the right medicine. This technology has the potential are showing signs that might help us achieve this goal the initial prospects."
According to Agence France-Presse reported, this study focused on mapping the most common and deadly brain tumor molecular characteristics of early, resulting in nuclear magnetic resonance scanning to distinguish it belongs to what type of seeds.
The paper published in the United States, "National Academy of Sciences" magazine published an advance on. Paper the main author, University of California, San Diego, Michael? Guo (sound) said that the same method can also be used to better identify other tumor types.
Guo and his research team used samples to be tested in vivo for different sub-types of cancer genetic structure, mapping, and these results provide in vivo mapping of samples of patients with MRI scan results were compared.
He said: "This is a powerful, scalable technology. It can be with different combination of scanning technology, but also can be applied to different types of tumors, such as liver cancer."
Although this technology for clinical applications still need to undergo further tests before, but it can help doctors confirm the future, what kind of treatment for the tumor sub-types of what to design a better treatment programs.
Guo said: "The medical goal is the right medicine. This technology has the potential are showing signs that might help us achieve this goal the initial prospects."
Friday, February 5, 2010
Peritoneal mesothelioma drug therapy
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Treatment
PMM moderately sensitive to chemotherapy drug. Preoperative induction chemotherapy, surgery and postoperative adjuvant chemotherapy could reduce tumor recurrence and improve 3-year survival rate.
PMM effects of chemical treatment of certain drugs doxorubicin, cisplatin, carboplatin, bleomycin and domestic anti-cancer drugs Eiemene so. Vincristine, fluorouracil, cyclophosphamide, mitomycin, also worth a try. Doxorubicin (Adriamycin, ADM) for each adult 30 ~ 60mg/m2, every 3 weeks a time, intravenous or intraperitoneal injection, total dose not exceed 550mg/m2. Adverse reactions to cardiac toxicity, as the, and there is accumulation of sex, and the total dose-related; followed by bone marrow suppression, gastrointestinal reactions and hair loss.
Cisplatin (Cisplatin, DDP, cis-platinum) Adult per 80 ~ 120mg/m2, every 3 weeks a time; or 20mg/m2, used in conjunction 5 days every 3 weeks for a course of treatment, intravenous injection. Adverse reactions are nephrotoxicity, ototoxicity, neurotoxicity, gastrointestinal reactions and inhibit bone marrow. Mannitol was added to reduce the accumulation in renal tubules.
Carboplatin (Carboplatin, CBP) for adults for each 300 ~ 400mg/m2, 5% glucose solution or saline, the diluted to the concentration of 0.5mg/ml solution, intravenous drip, repeated every 3 ~ 4 weeks, or 100mg / d by adding 500ml of 5% glucose solution intravenously qd for 5 days; 3 ~ 4 weeks to repeat one time. Can also be used for each intraperitoneal injection of 300 ~ 500mg per week, an times.
Bleomycin (Bleomycin, BLM) for adults 15 ~ 30mg, dissolved in an appropriate saline or 5% glucose solution in the deep intramuscular injection, intravenous injection or intravenous drip, 2 times per week; also be replaced by a second depending on the circumstances / d, or several times a week. Can also be used intraperitoneal injection of 60mg slowly dissolved. Stey intraperitoneal injection with BLM treatment of 1 case PMM patients, the results of ascites disappeared after stopping does not occur again, survive more than 3 years. However, BLM intraperitoneal injection of large doses can cause pneumonia-like symptoms, or pulmonary fibrosis; In addition, fever, gastrointestinal reactions more common, occurring allergic individual patients.
Taxol (Paclitaxel) This product is extracted from the bark of Taxus anticancer drugs, by inducing and promoting tubulin polymerization and stability to prevent depolymerization of microtubules, inhibit cell division and proliferation. Paclitaxel can inhibit mitotic microtubule network required for regeneration, prevent the formation of the mitotic spindle leading to chromosome breaks, inhibition of tumor cell replication. Dose of 135 ~ 175 mg/m2, diluted in normal saline or 5% glucose solution intravenously. Repeated every 3 weeks. 12 hours before treatment should be given dexamethasone 20 mg, 30 ~ 60 minutes ago to be intravenous diphenhydramine 50 mg and cimetidine 300 mg or ranitidine 200 mg, to prevent allergic reactions. Cis-platinum combined with about 66.7% of patients on the force and capability by its toxicity. Adverse reactions are bone marrow suppression, allergic reactions, arthralgia, myalgia, gastrointestinal reactions, peripheral neuropathy, syncope, ataxia, and injection site pain and swelling and so on.
Eiemene (Elemene) Curcuma extract of traditional Chinese medicine to the anti-cancer active substance; chest, intra-abdominal perfusion in the treatment of malignant chest, ascites has good curative effect. In as far as possible after the extraction ascites by intraperitoneal injection of 200 ~ 400mg/m2 usage, 1 ~ 2 times a week. The incidence of adverse reactions was 20% ~ 70%, mainly fever, chills and pain; such as a pre-injection of a small amount of narcotic drugs and hormones, are able to prevent them; other allergic reactions, gastrointestinal reactions.
Cyclophosphamide (CTX) for adults for each 600 ~ 1200mg, week 1 ~ 2 times, intravenous injection. After treatment of bone marrow suppression, gastrointestinal reactions and hemorrhagic adverse events than those in common bladder Yandeng.
Vincristine (VCR) for adults per 2.5 ~ 8mg/m2, week 1, intravenous injection, total volume of 60 ~ 80mg, major adverse reactions of bone marrow suppression.
Methotrexate (MTX) for adults every 15 ~ 50mg, week 1 ~ 2 times, muscle or intravenously. Side effects are bone marrow suppression, gastrointestinal reactions, stomatitis, liver and kidney dysfunction, etc., long-term medication can cause pulmonary fibrosis.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Treatment
PMM moderately sensitive to chemotherapy drug. Preoperative induction chemotherapy, surgery and postoperative adjuvant chemotherapy could reduce tumor recurrence and improve 3-year survival rate.
PMM effects of chemical treatment of certain drugs doxorubicin, cisplatin, carboplatin, bleomycin and domestic anti-cancer drugs Eiemene so. Vincristine, fluorouracil, cyclophosphamide, mitomycin, also worth a try. Doxorubicin (Adriamycin, ADM) for each adult 30 ~ 60mg/m2, every 3 weeks a time, intravenous or intraperitoneal injection, total dose not exceed 550mg/m2. Adverse reactions to cardiac toxicity, as the, and there is accumulation of sex, and the total dose-related; followed by bone marrow suppression, gastrointestinal reactions and hair loss.
Cisplatin (Cisplatin, DDP, cis-platinum) Adult per 80 ~ 120mg/m2, every 3 weeks a time; or 20mg/m2, used in conjunction 5 days every 3 weeks for a course of treatment, intravenous injection. Adverse reactions are nephrotoxicity, ototoxicity, neurotoxicity, gastrointestinal reactions and inhibit bone marrow. Mannitol was added to reduce the accumulation in renal tubules.
Carboplatin (Carboplatin, CBP) for adults for each 300 ~ 400mg/m2, 5% glucose solution or saline, the diluted to the concentration of 0.5mg/ml solution, intravenous drip, repeated every 3 ~ 4 weeks, or 100mg / d by adding 500ml of 5% glucose solution intravenously qd for 5 days; 3 ~ 4 weeks to repeat one time. Can also be used for each intraperitoneal injection of 300 ~ 500mg per week, an times.
Bleomycin (Bleomycin, BLM) for adults 15 ~ 30mg, dissolved in an appropriate saline or 5% glucose solution in the deep intramuscular injection, intravenous injection or intravenous drip, 2 times per week; also be replaced by a second depending on the circumstances / d, or several times a week. Can also be used intraperitoneal injection of 60mg slowly dissolved. Stey intraperitoneal injection with BLM treatment of 1 case PMM patients, the results of ascites disappeared after stopping does not occur again, survive more than 3 years. However, BLM intraperitoneal injection of large doses can cause pneumonia-like symptoms, or pulmonary fibrosis; In addition, fever, gastrointestinal reactions more common, occurring allergic individual patients.
Taxol (Paclitaxel) This product is extracted from the bark of Taxus anticancer drugs, by inducing and promoting tubulin polymerization and stability to prevent depolymerization of microtubules, inhibit cell division and proliferation. Paclitaxel can inhibit mitotic microtubule network required for regeneration, prevent the formation of the mitotic spindle leading to chromosome breaks, inhibition of tumor cell replication. Dose of 135 ~ 175 mg/m2, diluted in normal saline or 5% glucose solution intravenously. Repeated every 3 weeks. 12 hours before treatment should be given dexamethasone 20 mg, 30 ~ 60 minutes ago to be intravenous diphenhydramine 50 mg and cimetidine 300 mg or ranitidine 200 mg, to prevent allergic reactions. Cis-platinum combined with about 66.7% of patients on the force and capability by its toxicity. Adverse reactions are bone marrow suppression, allergic reactions, arthralgia, myalgia, gastrointestinal reactions, peripheral neuropathy, syncope, ataxia, and injection site pain and swelling and so on.
Eiemene (Elemene) Curcuma extract of traditional Chinese medicine to the anti-cancer active substance; chest, intra-abdominal perfusion in the treatment of malignant chest, ascites has good curative effect. In as far as possible after the extraction ascites by intraperitoneal injection of 200 ~ 400mg/m2 usage, 1 ~ 2 times a week. The incidence of adverse reactions was 20% ~ 70%, mainly fever, chills and pain; such as a pre-injection of a small amount of narcotic drugs and hormones, are able to prevent them; other allergic reactions, gastrointestinal reactions.
Cyclophosphamide (CTX) for adults for each 600 ~ 1200mg, week 1 ~ 2 times, intravenous injection. After treatment of bone marrow suppression, gastrointestinal reactions and hemorrhagic adverse events than those in common bladder Yandeng.
Vincristine (VCR) for adults per 2.5 ~ 8mg/m2, week 1, intravenous injection, total volume of 60 ~ 80mg, major adverse reactions of bone marrow suppression.
Methotrexate (MTX) for adults every 15 ~ 50mg, week 1 ~ 2 times, muscle or intravenously. Side effects are bone marrow suppression, gastrointestinal reactions, stomatitis, liver and kidney dysfunction, etc., long-term medication can cause pulmonary fibrosis.
Monday, February 1, 2010
Peritoneal mesothelioma chemotherapy
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Chemotherapy:
To give a systemic anti-cancer chemotherapy drug, the peritoneal cavity less drug distribution. Foreign reports, whether single-agent or combination therapy, systemic chemotherapy, efficiency is only 11% ~ 14%. Combination chemotherapy programs include: DDP + ADM, DDP + CTX + VCR, CTX + VCR + BLM and so on. But many scholars stressed that the chemotherapy does not improve the curative effect. Poulain, etc. In vitro studies of the DDP, CBP and amphotericin B (AmB) in malignant mesothelioma cell lines in cytotoxicity. Cell line exposure to these drugs two hours, six days later --- inhibit the growth curve shows that the concentration of 5 ~ 10mg / L of AmB on sensitive or resistant cell lines to DDP, and CBP can be 50% of growth - inhibitory concentration (IC50) reduced by 5 ~ 10 times. The role of AmB may be associated with a significant increase in the tumor cells to platinum intake, increased intracellular concentration of platinum, platinum enhanced cytotoxic effects. Phosphodiesterase inhibition methylxanthine (phosphodiesterase inhibiting methylxanthines) and AmB had synergistic effect, its own toxicity is weak, and can alleviate the toxicity of AmB kidney. But so far no clinical report of the joint application of these drugs.
2 intraperitoneal chemotherapy in recent years that the intraperitoneal injection drug use can increase local drug concentrations, reducing systemic adverse reactions; not only the eradication of residual tumor tissue after surgery to reduce the recurrence; also allows partial loss surgery patients the opportunity to reduce the mass, ascites reduced, disease has been effectively controlled.
Intra-abdominal and intravenous dose once a dosage similar to or slightly higher than the latter; 1 week later to repeat. According to the disease can be a continuous injection for several weeks. Ito and so can not give one cases of surgical resection of patients with PMM intraperitoneal injection DDP, and the combination of uracil and tegafur, made an unexpected effect: In the 223 days after abdominal mass and ascites disappeared completely. But in the first 8 months after the recurrence of pelvic masses; re-awarded to DDP and camptothecin, the effect is poor. Ma, etc. are heated by continuous hyperthermic peritoneal perfusion (continuous hyperthermic peritoneal perfusion, CHPP) combined local injection of DDP treatment of PPM. The average amount of the initial DDP infusion 120mg/ml (81 ~ 166mg/ml), perfusion flow rate 1.5L/min, the average infusion volume of 5.1L (4 ~ 7L), reperfusion after 90 minutes, measuring intra-abdominal temperature were three 41.5 ℃, 40.5 ℃ and 41.1 ℃. DDP infusion fluid total area under the curve (AUC) for plasma DDP AUC 21-fold, plasma concentrations and systemic DDP when medication is similar. Course of treatment, no significant local adverse reactions, patients are able to tolerate CHPP. Follow-up of 10 months, no one cases of death due to CHPP treatment. Park, also has similar coverage. It seems now, CHPP as good for the treatment of PMM is an effective way.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Chemotherapy:
To give a systemic anti-cancer chemotherapy drug, the peritoneal cavity less drug distribution. Foreign reports, whether single-agent or combination therapy, systemic chemotherapy, efficiency is only 11% ~ 14%. Combination chemotherapy programs include: DDP + ADM, DDP + CTX + VCR, CTX + VCR + BLM and so on. But many scholars stressed that the chemotherapy does not improve the curative effect. Poulain, etc. In vitro studies of the DDP, CBP and amphotericin B (AmB) in malignant mesothelioma cell lines in cytotoxicity. Cell line exposure to these drugs two hours, six days later --- inhibit the growth curve shows that the concentration of 5 ~ 10mg / L of AmB on sensitive or resistant cell lines to DDP, and CBP can be 50% of growth - inhibitory concentration (IC50) reduced by 5 ~ 10 times. The role of AmB may be associated with a significant increase in the tumor cells to platinum intake, increased intracellular concentration of platinum, platinum enhanced cytotoxic effects. Phosphodiesterase inhibition methylxanthine (phosphodiesterase inhibiting methylxanthines) and AmB had synergistic effect, its own toxicity is weak, and can alleviate the toxicity of AmB kidney. But so far no clinical report of the joint application of these drugs.
2 intraperitoneal chemotherapy in recent years that the intraperitoneal injection drug use can increase local drug concentrations, reducing systemic adverse reactions; not only the eradication of residual tumor tissue after surgery to reduce the recurrence; also allows partial loss surgery patients the opportunity to reduce the mass, ascites reduced, disease has been effectively controlled.
Intra-abdominal and intravenous dose once a dosage similar to or slightly higher than the latter; 1 week later to repeat. According to the disease can be a continuous injection for several weeks. Ito and so can not give one cases of surgical resection of patients with PMM intraperitoneal injection DDP, and the combination of uracil and tegafur, made an unexpected effect: In the 223 days after abdominal mass and ascites disappeared completely. But in the first 8 months after the recurrence of pelvic masses; re-awarded to DDP and camptothecin, the effect is poor. Ma, etc. are heated by continuous hyperthermic peritoneal perfusion (continuous hyperthermic peritoneal perfusion, CHPP) combined local injection of DDP treatment of PPM. The average amount of the initial DDP infusion 120mg/ml (81 ~ 166mg/ml), perfusion flow rate 1.5L/min, the average infusion volume of 5.1L (4 ~ 7L), reperfusion after 90 minutes, measuring intra-abdominal temperature were three 41.5 ℃, 40.5 ℃ and 41.1 ℃. DDP infusion fluid total area under the curve (AUC) for plasma DDP AUC 21-fold, plasma concentrations and systemic DDP when medication is similar. Course of treatment, no significant local adverse reactions, patients are able to tolerate CHPP. Follow-up of 10 months, no one cases of death due to CHPP treatment. Park, also has similar coverage. It seems now, CHPP as good for the treatment of PMM is an effective way.
Wednesday, January 27, 2010
Biochemical treatment of peritoneal mesothelioma
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Biological response modifier therapy:
Biological response modifiers (biological response modifier, BRM) some of the body's own cells and molecules, can answer to stimulate the body's internal and external environment, and to participate in the body to maintain environmental stability. BRM through the mobilization of the inherent capacity of the body to resist and eliminate cancer, become the new mode of treatment of cancer. With the cell engineering and genetic engineering progress, BRM come in handy in the field of cancer therapy.
Cytokines: interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), etc. In addition to direct anti-tumor cells, and can be activated in vivo anti-cancer cells, or secretion of anti-cancer effects of molecules, or maintain the immune response cell proliferation and differentiation features, PMM can be used as adjuvant therapy.
Adoptive transfer of immune cells: collection, separation of malignant ascites in the lymphocytes, in vitro expansion, and induces cytotoxicity issued Lymphokine Activated Killer cells (LAK cells) and integrate it into the body, there are anti-tumor cells. At the same time to give IL-2, can improve efficacy. Tani and so will the patient's own lymphocytes and malignant mesothelioma cells in mixed culture, to be anti-monoclonal antibody and IL-2 activation of the generated cytotoxic T cells (CTL). Activated CTL against malignant mesothelioma cells have a high degree of self-cytotoxicity. PMM to the two cases reported in the literature, while patients with chemotherapy, intra-abdominal injection of CTL as an auxiliary therapy, the results of ascites subsided gradually disappeared tumor blocks, improving the patient's quality of life.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
Biological response modifier therapy:
Biological response modifiers (biological response modifier, BRM) some of the body's own cells and molecules, can answer to stimulate the body's internal and external environment, and to participate in the body to maintain environmental stability. BRM through the mobilization of the inherent capacity of the body to resist and eliminate cancer, become the new mode of treatment of cancer. With the cell engineering and genetic engineering progress, BRM come in handy in the field of cancer therapy.
Cytokines: interleukin (IL), interferon (IFN), tumor necrosis factor (TNF), etc. In addition to direct anti-tumor cells, and can be activated in vivo anti-cancer cells, or secretion of anti-cancer effects of molecules, or maintain the immune response cell proliferation and differentiation features, PMM can be used as adjuvant therapy.
Adoptive transfer of immune cells: collection, separation of malignant ascites in the lymphocytes, in vitro expansion, and induces cytotoxicity issued Lymphokine Activated Killer cells (LAK cells) and integrate it into the body, there are anti-tumor cells. At the same time to give IL-2, can improve efficacy. Tani and so will the patient's own lymphocytes and malignant mesothelioma cells in mixed culture, to be anti-monoclonal antibody and IL-2 activation of the generated cytotoxic T cells (CTL). Activated CTL against malignant mesothelioma cells have a high degree of self-cytotoxicity. PMM to the two cases reported in the literature, while patients with chemotherapy, intra-abdominal injection of CTL as an auxiliary therapy, the results of ascites subsided gradually disappeared tumor blocks, improving the patient's quality of life.
Monday, January 25, 2010
Related to the treatment of peritoneal mesothelioma
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
PMM for the rare peritoneal malignancy, has always held that the prognosis is poor, so far there is no standardized treatment protocols, but this situation is expected to change. In recent years, based on surgery, chemotherapy, radiotherapy, immune therapy has been supplemented by a combination therapy began to take shape.
On the chief complaint of chronic abdominal pain, abdominal distention, the elderly patients, especially those with ascites, and (or) abdominal mass who, by ultrasound or CT examination confirmed the intra-abdominal mass or peritoneal nodules on; ascites was exudative ascites and transparent quality acid was significantly higher; serum CA125 increase should be highly suspected PMM. For these patients should be ultrasound or CT guided biopsy, laparoscopy, or laparotomy; in estimating the range of tumor spread, while visceral and parietal peritoneum in multiple biopsy to obtain adequate organization for pathological examination and organization of the immune or chemical examination. Most patients diagnosed PMM, has been difficult to completely remove the tumor surgery. If no obstruction performance, should provide 2 to 3 treatment-induced intra-abdominal chemotherapy, in order to minimize the surface of tumor growing in the intestine, in order to create the conditions for surgery and help clinicians master the tumor response to chemotherapy information. After induction chemotherapy in 2 months, the purposes of cytoreductive surgery, removal of peritoneal disease, so as to remove all tumor tissue. Intraoperative or early postoperative intraperitoneal should be given adjuvant chemotherapy, and adjuvant treatment with radiotherapy and BRM. On postoperative tumor recurrence, such as conditions permit, consideration should be given re-operation.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
PMM for the rare peritoneal malignancy, has always held that the prognosis is poor, so far there is no standardized treatment protocols, but this situation is expected to change. In recent years, based on surgery, chemotherapy, radiotherapy, immune therapy has been supplemented by a combination therapy began to take shape.
On the chief complaint of chronic abdominal pain, abdominal distention, the elderly patients, especially those with ascites, and (or) abdominal mass who, by ultrasound or CT examination confirmed the intra-abdominal mass or peritoneal nodules on; ascites was exudative ascites and transparent quality acid was significantly higher; serum CA125 increase should be highly suspected PMM. For these patients should be ultrasound or CT guided biopsy, laparoscopy, or laparotomy; in estimating the range of tumor spread, while visceral and parietal peritoneum in multiple biopsy to obtain adequate organization for pathological examination and organization of the immune or chemical examination. Most patients diagnosed PMM, has been difficult to completely remove the tumor surgery. If no obstruction performance, should provide 2 to 3 treatment-induced intra-abdominal chemotherapy, in order to minimize the surface of tumor growing in the intestine, in order to create the conditions for surgery and help clinicians master the tumor response to chemotherapy information. After induction chemotherapy in 2 months, the purposes of cytoreductive surgery, removal of peritoneal disease, so as to remove all tumor tissue. Intraoperative or early postoperative intraperitoneal should be given adjuvant chemotherapy, and adjuvant treatment with radiotherapy and BRM. On postoperative tumor recurrence, such as conditions permit, consideration should be given re-operation.
Wednesday, January 20, 2010
The anti-liver cancer drug --- Raspberry
Raspberries are rich in a large number of "Tanning acid" that can inhibit tumor growth. In addition, grapes, apples and other fruits are also inhibit tumor cell proliferation.
Beauty beauty of fruit can be added vitamins, but the 4th Hospital of Harbin Medical University experts found that its more important role: the prevention of primary liver cancer. Recently, Jin was admitted four hospital Dr. Liu Ming, vice president of applications, "the National Natural Science Foundation of China Project" has been approved, Dr. Liu Ming of the fruit began formal study of the role of liver cancer. The near future, prone to liver cancer in high-risk groups will be able to enjoy the results of this study.
Jin was admitted four homes, according to Dr. Liu Ming, vice president of introduction, raspberry-rich large number of "Tanning acid" that can inhibit tumor growth. In addition, grapes, apples and other fruits are also inhibit tumor cell proliferation. At present, Liu has established a raspberry prevention of primary liver cancer study group, and from Shangzhi purchased a large quantity of raspberry repeated studies. If successful, they can take advantage of raspberry extract in the production of pharmaceutical preparations or oral, for the use of high-risk groups susceptible to liver cancer. Liu said that the liver is called the "cancer of the King", once contracted, is very small chance of cure. Hepatitis B virus carriers, rural long-term consumption of moldy grain populations, and have a family genetic history of the long-term consumption of high-risk groups if raspberry, grape and other fruits, can effectively prevent primary liver cancer.
On how a reasonable intake of fruits, Liu made the following three proposals: First, at least a day eating grapes, apples, oranges, etc., or two or more fruit, if and cauliflower, tomatoes, carrots and other vegetables with consumption of three or more, the effect is more good; Second, grapes, apples and other fruits soaked, cleaned, it is best consumed as a whole, not peeled; three daily intake of vegetables and fruits, not less than 400-500 grams, and the fruits, vegetables, varieties should be diverse .
Beauty beauty of fruit can be added vitamins, but the 4th Hospital of Harbin Medical University experts found that its more important role: the prevention of primary liver cancer. Recently, Jin was admitted four hospital Dr. Liu Ming, vice president of applications, "the National Natural Science Foundation of China Project" has been approved, Dr. Liu Ming of the fruit began formal study of the role of liver cancer. The near future, prone to liver cancer in high-risk groups will be able to enjoy the results of this study.
Jin was admitted four homes, according to Dr. Liu Ming, vice president of introduction, raspberry-rich large number of "Tanning acid" that can inhibit tumor growth. In addition, grapes, apples and other fruits are also inhibit tumor cell proliferation. At present, Liu has established a raspberry prevention of primary liver cancer study group, and from Shangzhi purchased a large quantity of raspberry repeated studies. If successful, they can take advantage of raspberry extract in the production of pharmaceutical preparations or oral, for the use of high-risk groups susceptible to liver cancer. Liu said that the liver is called the "cancer of the King", once contracted, is very small chance of cure. Hepatitis B virus carriers, rural long-term consumption of moldy grain populations, and have a family genetic history of the long-term consumption of high-risk groups if raspberry, grape and other fruits, can effectively prevent primary liver cancer.
On how a reasonable intake of fruits, Liu made the following three proposals: First, at least a day eating grapes, apples, oranges, etc., or two or more fruit, if and cauliflower, tomatoes, carrots and other vegetables with consumption of three or more, the effect is more good; Second, grapes, apples and other fruits soaked, cleaned, it is best consumed as a whole, not peeled; three daily intake of vegetables and fruits, not less than 400-500 grams, and the fruits, vegetables, varieties should be diverse .
Friday, January 15, 2010
How to prevent peritoneal mesothelioma
Peritoneal malignant mesothelioma, also known as primary peritoneal mesothelioma, is originated in the peritoneal epithelium and mesothelial cancer organizations. The disease compared with pleural mesothelioma, a rare, slightly higher for men. Benign mesothelioma'll always be single, multi-located in the fallopian tubes, uterus at the top of the peritoneum, other parts of the rare. Malignant mesothelioma is often diffuse, covering all or part of the peritoneum.
Peritoneal mesothelioma originated in the peritoneal epithelium and mesothelial organizations, asbestos dust for the disease-causing substances, may also be caused by certain viruses causes of mesothelioma. Active steps to prevent occupational diseases (such as textiles, construction) is the key to prevention of this disease.
Peritoneal mesothelioma originated in the peritoneal epithelium and mesothelial organizations, asbestos dust for the disease-causing substances, may also be caused by certain viruses causes of mesothelioma. Active steps to prevent occupational diseases (such as textiles, construction) is the key to prevention of this disease.
Sunday, January 10, 2010
What are cancer preventive measures?
Do not smoke. There are a variety of cigarette smoke carcinogens such as benzopyrene dimethylnitrosamine, radioactive elements ZIOPO and phenolic compounds, seriously harmful substances are nicotine, carbon monoxide and tar, etc., about 70 lung cancer patients in China % -80% is caused due to long-term smokers.
1, do not smoke. There are a variety of cigarette smoke carcinogens such as benzopyrene dimethylnitrosamine, radioactive elements ZIOPO and phenolic compounds, seriously harmful substances are nicotine, carbon monoxide and tar, etc., about 70 lung cancer patients in China % -80% is caused due to long-term smokers.
2, promoting a scientific diet. Gastrointestinal cancer in China more than 65%, mainly related to water pollution, improper diet or pollution related to dietary fat, protein and carbohydrate structure should be in line with the proportion of health in order to plant food-based, with appropriate vegetables to avoid high-fat, high protein, high-calorie diet, can reduce colorectal cancer, colon cancer, prostate cancer, pancreatic cancer, breast cancer, endometrial cancer, ovarian cancer, and so place.
3, eat moldy and moldy food. Are known to have more than 20 kinds of molds and their toxins have carcinogenic effects in experimental animals, such as aflatoxin B1 are their representatives, our high incidence of esophageal cancer, liver cancer and other income related to the consumption of food contaminated with mold is closely related to.
4, do not drink alcohol or less. Alcohol not only to cirrhosis and liver cancer, but also with the brain, the occurrence of laryngeal cancer, has proven drinking 20-30 grams per day for women suffering from breast cancer more likely than women who never drink 2 times higher.
5, to prevent food contamination. Primarily to prevent the spread of infection or cancer-causing micro-organisms, strict control and monitoring of food additives.
6, to avoid or reduce occupational carcinogen. Because some types of work and workshops with high levels of cancer-causing agent, thus causing a higher incidence of cancer, at present has proved to be kerosene, tar, asphalt, fungi, asbestos, mustard gas, chromium and arsenic, benzene, radioactive substances, together aniline, B-benzene, carbonyl and nickel are carcinogenic, the need to strengthen prevention of occupational diseases.
1, do not smoke. There are a variety of cigarette smoke carcinogens such as benzopyrene dimethylnitrosamine, radioactive elements ZIOPO and phenolic compounds, seriously harmful substances are nicotine, carbon monoxide and tar, etc., about 70 lung cancer patients in China % -80% is caused due to long-term smokers.
2, promoting a scientific diet. Gastrointestinal cancer in China more than 65%, mainly related to water pollution, improper diet or pollution related to dietary fat, protein and carbohydrate structure should be in line with the proportion of health in order to plant food-based, with appropriate vegetables to avoid high-fat, high protein, high-calorie diet, can reduce colorectal cancer, colon cancer, prostate cancer, pancreatic cancer, breast cancer, endometrial cancer, ovarian cancer, and so place.
3, eat moldy and moldy food. Are known to have more than 20 kinds of molds and their toxins have carcinogenic effects in experimental animals, such as aflatoxin B1 are their representatives, our high incidence of esophageal cancer, liver cancer and other income related to the consumption of food contaminated with mold is closely related to.
4, do not drink alcohol or less. Alcohol not only to cirrhosis and liver cancer, but also with the brain, the occurrence of laryngeal cancer, has proven drinking 20-30 grams per day for women suffering from breast cancer more likely than women who never drink 2 times higher.
5, to prevent food contamination. Primarily to prevent the spread of infection or cancer-causing micro-organisms, strict control and monitoring of food additives.
6, to avoid or reduce occupational carcinogen. Because some types of work and workshops with high levels of cancer-causing agent, thus causing a higher incidence of cancer, at present has proved to be kerosene, tar, asphalt, fungi, asbestos, mustard gas, chromium and arsenic, benzene, radioactive substances, together aniline, B-benzene, carbonyl and nickel are carcinogenic, the need to strengthen prevention of occupational diseases.
Thursday, January 7, 2010
Concerned about the children's cancer "three early"
According to medical statistics, 0-14-year-old children, the incidence of malignant tumors accounted for 0.6% of all malignant tumors. Although the incidence is relatively low, but the high degree of malignancy and mortality accounted for 10.7% of child mortality, has become apart from unintentional injuries outside the main cause of child deaths. Children's cancer attributable to their lack of knowledge, the majority of patients with atypical symptoms, children complained of poor, as well as the lack of professional children's cancer doctor and other reasons, in which children can not be the early detection of cancer is often misdiagnosed or even, this is children's cancer patients are not at an early stage to be timely and correct diagnosis and treatment, resulting in an important factor in poor prognosis.
Children's cancer incidence rates according to the order of white blood and central nervous system tumors, malignant lymphoma, a variety of neuroblastoma (common for neuroblastoma, Wilms tumor, hepatoblastoma and retinoblastoma, etc.), abnormal Fetal tumors and rhabdomyosarcoma, osteosarcoma, and so on. They can occur in childhood of all ages, and some malignant tumors such as neuroblastoma may be derived from embryonic period, that is in the neonatal period have been discovered. More than the vast majority of tumors derived from the mother's pregnancy when the embryonic mesoderm of the non-epithelial cells of such tumors in the deeper parts of the body, in addition to the individual tumor outside (such as neuroblastoma specific neural enolase) At present there is no effective screening method of the crowd, it was found more difficult. Although the application of molecular techniques in recent years, there are some reports in the diagnosis, it is still at the research stage and not yet generally used in clinical. Therefore, the diagnosis of malignant tumors in children still rely on parents to detect the disease early leads and specialists in clinical diagnosis.
Parents cope with children are highly vigilant of the following symptoms: (1) systemic performance: longer-term fever, in particular by the short-term antiviral and antibiotic treatment ineffective heat; short-term significant weight loss, weight does not increase or decrease; weakness, Dai Juan; constantly increasing anemia, pale; endocrine disorders, such as asymmetrical such as obesity or precocious puberty. (2) Local performance: mainly local pain, swelling, as well as the surrounding organ mass produce a range of symptoms of oppression. Easier for the early detection of superficial lumps, but in the hidden parts of the body cavity is difficult to lump the early detection of the parents. Parents should note that at this point whether there is tumor compression of adjacent organs produce symptoms, such as mediastinal tumor may cause difficulty in breathing or hold your breath; abdominal gastrointestinal tract tumors often arise because of oppression, nausea, vomiting and intestinal obstruction symptoms; sacral or pelvic tumors can be lead to abnormal bowel movement or urination.
Once the parents found that the above-mentioned abnormal situation, it is timely to set up children's cancer specialist children's cancer hospital physician please check to make a timely diagnosis, so as not to delay treatment. Examination of children's cancer patients, including non-invasive, which means that pairs of children to conduct the inspection without pain, such as the X-ray plain films, B Chao, CT and other tests, more receptive to their families; a-invasive, which means that there is suffering on the children's inspection, such as lumbar puncture, bone marrow puncture, Biopsy examination and other family members are not always easy to accept, but sometimes it is only through these checks in order to obtain the scientific pathology. To make a correct diagnosis of the early development of rational treatment programs to improve treatment and survival rates are very critical. Such as early nephroblastoma (Ⅰ period) more than 90% cure rate, while the transfer time of diagnosis has been late (Ⅳ period) the patient's cure rate is only about 50%. Children's cancer and adult is different from many diseases at an early full access to life-long cure.
Early detection, early diagnosis and early treatment is to improve the efficacy and children's cancer survival rate important aspects. We make the following recommendations to parents: (1) information on the children's cancer of the popular science knowledge, improve the vigilance of the disease, if the conditions for regular medical examinations to children's oncology; (2) careful observation of the child's physical condition, abnormality was found in time to the Please oncology specialist hospitals, doctor checkups for children; (3) Do not believe in non-specialist medical diagnosis; (4) Do not refuse to doctors when necessary, the children engage in invasive examination; (5) Once diagnosed, treatment should be timely and reasonable .
Children's cancer incidence rates according to the order of white blood and central nervous system tumors, malignant lymphoma, a variety of neuroblastoma (common for neuroblastoma, Wilms tumor, hepatoblastoma and retinoblastoma, etc.), abnormal Fetal tumors and rhabdomyosarcoma, osteosarcoma, and so on. They can occur in childhood of all ages, and some malignant tumors such as neuroblastoma may be derived from embryonic period, that is in the neonatal period have been discovered. More than the vast majority of tumors derived from the mother's pregnancy when the embryonic mesoderm of the non-epithelial cells of such tumors in the deeper parts of the body, in addition to the individual tumor outside (such as neuroblastoma specific neural enolase) At present there is no effective screening method of the crowd, it was found more difficult. Although the application of molecular techniques in recent years, there are some reports in the diagnosis, it is still at the research stage and not yet generally used in clinical. Therefore, the diagnosis of malignant tumors in children still rely on parents to detect the disease early leads and specialists in clinical diagnosis.
Parents cope with children are highly vigilant of the following symptoms: (1) systemic performance: longer-term fever, in particular by the short-term antiviral and antibiotic treatment ineffective heat; short-term significant weight loss, weight does not increase or decrease; weakness, Dai Juan; constantly increasing anemia, pale; endocrine disorders, such as asymmetrical such as obesity or precocious puberty. (2) Local performance: mainly local pain, swelling, as well as the surrounding organ mass produce a range of symptoms of oppression. Easier for the early detection of superficial lumps, but in the hidden parts of the body cavity is difficult to lump the early detection of the parents. Parents should note that at this point whether there is tumor compression of adjacent organs produce symptoms, such as mediastinal tumor may cause difficulty in breathing or hold your breath; abdominal gastrointestinal tract tumors often arise because of oppression, nausea, vomiting and intestinal obstruction symptoms; sacral or pelvic tumors can be lead to abnormal bowel movement or urination.
Once the parents found that the above-mentioned abnormal situation, it is timely to set up children's cancer specialist children's cancer hospital physician please check to make a timely diagnosis, so as not to delay treatment. Examination of children's cancer patients, including non-invasive, which means that pairs of children to conduct the inspection without pain, such as the X-ray plain films, B Chao, CT and other tests, more receptive to their families; a-invasive, which means that there is suffering on the children's inspection, such as lumbar puncture, bone marrow puncture, Biopsy examination and other family members are not always easy to accept, but sometimes it is only through these checks in order to obtain the scientific pathology. To make a correct diagnosis of the early development of rational treatment programs to improve treatment and survival rates are very critical. Such as early nephroblastoma (Ⅰ period) more than 90% cure rate, while the transfer time of diagnosis has been late (Ⅳ period) the patient's cure rate is only about 50%. Children's cancer and adult is different from many diseases at an early full access to life-long cure.
Early detection, early diagnosis and early treatment is to improve the efficacy and children's cancer survival rate important aspects. We make the following recommendations to parents: (1) information on the children's cancer of the popular science knowledge, improve the vigilance of the disease, if the conditions for regular medical examinations to children's oncology; (2) careful observation of the child's physical condition, abnormality was found in time to the Please oncology specialist hospitals, doctor checkups for children; (3) Do not believe in non-specialist medical diagnosis; (4) Do not refuse to doctors when necessary, the children engage in invasive examination; (5) Once diagnosed, treatment should be timely and reasonable .
Sunday, January 3, 2010
Clinical staging of peritoneal mesothelioma
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM).
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
PMM lack of specific clinical manifestations, may have abdominal pain, constipation, abdominal distention, weight loss, and other intestinal obstruction performance. Physical examination can be found such as ascites or peritoneal mass. Ascites as exudate, in part to bloody. The disease often misdiagnosed as tuberculous peritonitis, recurrent spontaneous peritonitis, mesenteric inflammation or peritoneal metastasis of cancers. Ascites hyaluronic acid were significantly higher than 0.8g / L were found only in PMM. Ascites cytology has a certain value, but the results often hard to tell. Serum carbohydrate antigen -125 (CA125) increased to help diagnose the disease.
Clinical staging: Butchart others will PMM is divided into four: I tumors confined to peritoneal; Ⅱ tumors violation of intra-abdominal lymph nodes; Ⅲ tumors outside the intra-abdominal lymph node metastasis; Ⅳ period of distant metastasis. The classification will help select treatment. PMM has no effective standard treatment. Prognosis is poor, the survival period after diagnosis the median one-year survival of more than 2 years less than 20%. Mainly from cachexia or bowel obstruction, the cause of death is rarely associated with tumor distant metastasis.
Peritoneal mesothelioma (peritoneal mesothelioma) for the primary in the peritoneal epithelium and mesothelial cancer organizations, clinical rare. Can be categorized as pathological adenomatoid mesothelioma (adenomatoid mesothelioma), cystic mesothelioma (cystic mesothelioma) and malignant mesothelioma (peritoneal malignant mesothelioma, PMM). The first two are benign. Cystic mesothelioma more common in women, the cause is unknown, occur in the pelvic or accessories around, showing single or multiple cystic masses; patients often palpable abdominal mass due to the treatment. Malignant peritoneal mesothelioma (PMM) account for about 30% of malignant mesothelioma; its occurrence is closely related with exposure to asbestos, about 5% of patients had history of exposure; asbestos fiber intake by mouth, after translocation through the intestinal wall into the peritoneal and pleural metastasis from disease or from. From exposure to asbestos to diagnosis, the disease incubation period of up to 25 to 40 years. But the domestic 1951 ~ 1993 20 reported in the literature 161 cases of PMM in only 1 case had history of exposure to asbestos. ZHOU Ya-kang and other reported 47 cases of mesothelioma there are eight cases of malignant peritoneal mesothelioma, as well as the author collected two cases have history of exposure to asbestos. In the absence of asbestos-exposed populations, its incidence rate is about 1 person / 1 million person-years may be related to certain viral infections and genetic factors. PMM has reported 1 cases of foreign patients come into contact with more than 40 years ago, thorium dioxide colloid (Thorotrast). PMM often occurs in men over the age of 40. Visceral or parietal peritoneum can suffer from; and tumors can be a direct violation of abdominal and pelvic organs; 50% ~ 70% of patients with lymphatic and / or hematogenous metastasis of liver, kidney, adrenal gland, lung, bone and so on.
PMM lack of specific clinical manifestations, may have abdominal pain, constipation, abdominal distention, weight loss, and other intestinal obstruction performance. Physical examination can be found such as ascites or peritoneal mass. Ascites as exudate, in part to bloody. The disease often misdiagnosed as tuberculous peritonitis, recurrent spontaneous peritonitis, mesenteric inflammation or peritoneal metastasis of cancers. Ascites hyaluronic acid were significantly higher than 0.8g / L were found only in PMM. Ascites cytology has a certain value, but the results often hard to tell. Serum carbohydrate antigen -125 (CA125) increased to help diagnose the disease.
Clinical staging: Butchart others will PMM is divided into four: I tumors confined to peritoneal; Ⅱ tumors violation of intra-abdominal lymph nodes; Ⅲ tumors outside the intra-abdominal lymph node metastasis; Ⅳ period of distant metastasis. The classification will help select treatment. PMM has no effective standard treatment. Prognosis is poor, the survival period after diagnosis the median one-year survival of more than 2 years less than 20%. Mainly from cachexia or bowel obstruction, the cause of death is rarely associated with tumor distant metastasis.
Friday, January 1, 2010
Peritoneal mesothelioma clinical manifestations and diagnosis of
Peritoneal mesothelioma is the primary peritoneal mesothelial cells in the tumor. Does not have the characteristic clinical manifestations, common signs and symptoms include: abdominal pain, ascites, abdominal distention and abdominal mass and so on.
Peritoneal mesothelioma is the primary peritoneal mesothelial cells in the tumor. Does not have the characteristic clinical manifestations, common signs and symptoms include: abdominal pain, ascites, abdominal distention and abdominal mass and so on. Peritoneal mesothelioma accounts for about 20% of all mesothelioma cases may occur in 2-92 years, mean age was 54 years, of which about 63% of cases are 45-64 years of age, children are rarely sick.
Clinical
1. Abdominal pain, abdominal distention, ascites, abdominal mass; 2. Anorexia, nausea, vomiting, diarrhea, constipation; 3. Fatigue, fever, weight loss, anemia; 4. Low blood sugar, diffuse abdominal ossification; 5. Combined with other parts, such as peritoneal mesothelioma, mesothelioma, metastasis to other organs and complications of the corresponding performance.
Diagnosis based on
1. Abdominal pain, abdominal distention, ascites, abdominal mass in patients, especially those with asbestos exposure history; 2. Imaging studies have a thin sheet of peritoneal signs and ascites tumor; 3. Ascites cytology; 4. Peritoneal biopsy, laparoscopic and laparotomy and pathological examination can be taken to make the organization confirmed.
Peritoneal mesothelioma is the primary peritoneal mesothelial cells in the tumor. Does not have the characteristic clinical manifestations, common signs and symptoms include: abdominal pain, ascites, abdominal distention and abdominal mass and so on. Peritoneal mesothelioma accounts for about 20% of all mesothelioma cases may occur in 2-92 years, mean age was 54 years, of which about 63% of cases are 45-64 years of age, children are rarely sick.
Clinical
1. Abdominal pain, abdominal distention, ascites, abdominal mass; 2. Anorexia, nausea, vomiting, diarrhea, constipation; 3. Fatigue, fever, weight loss, anemia; 4. Low blood sugar, diffuse abdominal ossification; 5. Combined with other parts, such as peritoneal mesothelioma, mesothelioma, metastasis to other organs and complications of the corresponding performance.
Diagnosis based on
1. Abdominal pain, abdominal distention, ascites, abdominal mass in patients, especially those with asbestos exposure history; 2. Imaging studies have a thin sheet of peritoneal signs and ascites tumor; 3. Ascites cytology; 4. Peritoneal biopsy, laparoscopic and laparotomy and pathological examination can be taken to make the organization confirmed.
Subscribe to:
Posts (Atom)